

Product Data Sheet

SARS-CoV-2-IN-32

Cat. No.: HY-151477
CAS No.: 96068-42-7

Molecular Formula: $C_{27}H_{23}N_5O_4$ Molecular Weight: 481.5

Target: SARS-CoV

Pathway: Anti-infection

Storage: Please store the product under the recommended conditions in the Certificate of

Analysis.

Result:

HO OH N-N

BIOLOGICAL ACTIVITY

Description	SARS-CoV-2-IN-32 (compound 3g) is a COVID-19 inhibitor. SARS-CoV-2-IN-32 shows anti-proliferative activity against cancer cells. SARS-CoV-2-IN-32 exhibits comparatively high binding affinity (-8.8 Kcal/mole) to COVID-19 main protease (M ^{pro}) (PDB ID: 6LU7). SARS-CoV-2-IN-32 can be used in studies of cancer and COVID-19 ^[1] .	
IC ₅₀ & Target	COVID-19 ^[1] .	
In Vitro	SARS-CoV-2-IN-32 (0-40 μ M; 48 h) exhibits antiproliferative activity in MCF-7, MDA-MB-231, HeLa and PC-3 cells ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Cell Proliferation Assay ^[1]	
	Cell Line:	MCF-7, MDA-MB-231, HeLa, PC-3, Ishikawa, HEK-293
	Concentration:	0-40 μΜ
	Incubation Time:	48 h

REFERENCES

[1]. Gupta A, et al. Visible Light-Promoted Green and Sustainable Approach for One-Pot Synthesis of 4, 4'-(Arylmethylene) bis (1H-pyrazol-5-ols), In Vitro Anticancer Activity, and Molecular Docking with Covid-19 Mpro. ACS Omega, 2022.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Inhibited proliferation of MCF-7, MDA-MB-231, HeLa, PC-3, Ishikawa, HEK-293 cells with IC

50 values of 35.64, 39.56, 38.32, 35.38, >40 and >40 μM, respectively.

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA